ALK-Abelló

ALK-Abelló A/S
TypeAktieselskab
Nasdaq Copenhagen: ALK B
IndustryPharmaceuticals
Founded1923 Copenhagen
FounderKaj Hedemann Baagøe Peter Barfod
HeadquartersHørsholm, Denmark
Key peopleAnders Hedegaard (Chairman)
Peter Halling (CEO)
ProductsAcarizax, Grazax, SlitOneUltra, Alutard SQ, Jext
RevenueIncrease DKK 4.824 billion (2023)
Number of employees
2,900 (2023)
Websitewww.alk.net

ALK-Abelló A/S (Nasdaq Copenhagen: ALK B), also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy (AIT) products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products (also known as ‘allergy vaccines’) with 67% of its revenue coming from sales in Europe.